A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

Expertise from Forbes Councils members, operated under license. Opinions expressed are those of the author. In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout ...

Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

A top US regulator plans to unveil a faster approach to approving custom gene-editing treatments, a move designed to unleash a wave of industry investment that will yield cures for patients with rare ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

A U.S. regulator reportedly plans to unveil a faster approach to approving custom gene-editing treatments for rare diseases.

“It’s something we need to pay attention to, especially as CRISPR expands to more diseases,” Sam Kulkarni, the CEO of CRISPR Therapeutics, which was not involved with either study, tells STAT News.

Researchers have identified molecular mechanisms behind age-related memory decline — and shown they can be reversed.

For many people interested in genome engineering, the era “before CRISPR” has faded into the deepest recesses of the mind, like a lost period of antiquity, even though it only entered the biotech ...

High-rolling investors have positioned themselves bearish on CRISPR Therapeutics (NASDAQ:CRSP), and it's important for retail traders to take note. \This activity came to our attention today through ...